The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients

Clinical Nuclear Medicine

Volumn 37, Issue 5, 2012, Pages 447-452

  Kobayashi, Maiko ^a   Kaida, Hayato ^a   Kawahara, Akihiko ^b   Hattori, Satoshi ^a   Kurata, Seiji ^a   Hayakawa, Masanobu ^a   Hirose, Yasumitsu ^a   Uchida, Masafumi ^a   Kage, Masayoshi ^b   Fujita, Hiromasa ^a   Hayabuchi, Naofumi ^a   Ishibashi, Masatoshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

18F FDG; esophageal; GLUT; squamous cell cancer; VEGF

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859631179     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31823924bb     Document Type: Article

References (35)

1. Kwee RM. Prediction of tumor response to neoadjuvant chemotherapy in patients with esophageal cancer with use of 18F-FDG PET: a systemic review. Radiology. 2010;254:707-717.
2. Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115-122.
3. Duong CP, Demitriou H, Weih L, et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2006;33:759-769. (Pubitemid 43979683)
4. Jingu K, Kaneta T, Nemoto K, et al. 18F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. Int J Clin Oncol. 2010;15:184-190.
5. Rajendran JG, Wilson DC, Corad EU, et al. [18] FMISO and [18] FDG PET imaging in soft tissue sarcoma: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695-704. (Pubitemid 36612952)
6. Byeon JS, Jung HY, Lee YJ, et al. Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma. J Gastroenterol Hepatol. 2004;19:648-654. (Pubitemid 38858197)
7. O-charoentrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92:556-568.
8. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small cell lung cancer. Int J Cancer. 2000;89: 475-483.
9. Nomiya T, Nemoto K, Miyachi H, et al. Relationship between radiosensitivity and microvascular density in esophageal carcinoma: significance of hypoxic fraction. Int J Radiat Oncol Biol Phys. 2004;58:589-596. (Pubitemid 38145594)
10. Airley RE, Mobashrei A. Hypoxic regulation of glucose transporter, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007;53:233-256. (Pubitemid 47074647)
11. Sobin LH, Wittekind CH (International Union Against Cancer), eds. TNM Classification of Malignant Tumors. 6th ed. Baltimore, MD: Wiley-Liss; 2002: 52-56.
12. Nguyen XC, So Y, Chung JH, et al. High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2F18- fluro-D-glucose uptake. Eur J Cancer. 2008;44:692-698.
13. Tateishi U, Yamaguchi U, Seki K, et al. Glut-1 expression and enhanced glucose metabolism are associated with tumor grade in bone and soft tissue sarcomas: a prospective evaluation by [18F] fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:683-691. (Pubitemid 43846759)
14. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180. (Pubitemid 34151039)
15. Tohma T, Okazumi S, Makino H, et al. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology. 2005; 52:486-490. (Pubitemid 40469453)
16. Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F- fluorodeoxyglucose (FDG) accumulation with glucose transporter (GLUT-1) expression in esophageal squamous cell carcinoma. Anticancer Res. 2003;23:3263-3272. (Pubitemid 36975422)
17. Taylor MD, Smith PW, Brix WK, et al. Correlation between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothoracic Surg. 2009;137:699-705.
18. Hiyoshi Y, Watanabe M, Imamura Y, et al. The relationship between the glucose transporter type 1 expression and 18F-fluorodeoxyglucose uptake in esophageal squamous carcinoma. Oncology. 2009;76:286-292.
19. 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115:3196-3293.
20. Takenaka T, Yano T, Ito K, et al. Biological significance of the maximum standardized uptake value on positron emission tomography in non-small cell lung cancer. J Surg Oncol. 2009;100:688-692.
21. Kaira K, Oriuchi N, Shimizu K, et al. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci. 2009;100:753-758.
22. Strauss LG, Koczan D, Klippel S, et al. Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med. 2008;49:1238-1244.
23. Penderson MW, Holm S, Lund EL, et al. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia. 2001;3:80-87. (Pubitemid 32201613)
24. 18F-FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol. 2008;134:227-236.
25. Choi JY, Jang KT, Shim YM, et al. Prognostic significance of vascular endothelial growth factor and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography. Ann Surg Oncol. 2006;13:1054-1062. (Pubitemid 44337964)
26. Inoue K, Ozeki Y, Suganuma T, et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer. 1997;79:206-213.
27. Kitadai Y, Haruma K, Tokutomi T, et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res. 1998;4:2195-2200. (Pubitemid 28415667)
28. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma. Cancer Lett. 2007;249:171-177. (Pubitemid 46452923)
29. Kim TF, Kim HY, Lee KW, et al. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2009;29:403-421.
30. Matsuyama T, Nakanishi K, Hayashi T, et al. Expression of hypoxia- inducible factor-1 α in esophageal squamous cell carcinoma. Cancer Sci. 2005;96:176-182. (Pubitemid 40575919)
31. Kaira K, Endo M, Abe M, et al. Biologic correlation of 2-[18F]-fluoro-2- deoxyglucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746-3753.
32. 18F-FDG uptake and prognostic impact in lung adenocarcinoma. J Nucl Med. 2006;47:419-425.
33. 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-435.
34. Sirinivas SM, Dhurairaj T, Basu S, et al. A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med. 2009;23: 341-348.
35. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.